The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.
Genentech announced on Wednesday that it has seen positive topline results from Archway, its Phase III study looking into its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular or “wet” age-related macular degeneration.
The funding will be used to continue to build the company’s technology and automation, which enable data generation at a larger scale. This will expand Insitro’s ability to create predictive models of human disease.
Legend Biotech, a clinical stage oncology biotech company, filed with the U.S. Securities and Exchange Commission on Wednesday to raise up to $100 million in an initial public offering.
Although many cyber criminals have pledged not to attack healthcare providers during the COVID-19 pandemic, one expert tells CNBC that this may not extend to pharmaceutical companies.
The company, which was founded in 2019, has a pipeline that includes multiple AAV-based gene therapies for the treatment of type 1 and type 2 diabetes, as well as obesity.
A new report released on Tuesday by GlobalData suggested that there was a 16% decrease in new drug approvals (NDAs) by the U.S. Food and Drug Administration last year.
A study published on May 8 in Science Advances by researchers at the Washington University School of Medicine in St. Louis suggested that gene therapy may be helpful for building strength and significant muscle mass quickly in the body.
A study published by researchers from The Mount Sinai Hospital/Mount Sinai School of Medicine on May 6 revealed that blood thinners may slow down clotting in patients with COVID-19, ultimately improving their chances of survival.
As the world continues to grapple with the effects of the COVID-19 pandemic, healthcare analysts are starting to wonder how the outbreak will impact drug development.
The CD19-directed chimeric antigen receptor (CAR) T cell therapy is a treatment for adults with relapsed or refractory large B-cell lymphoma after at least two prior therapies.
Praxis is currently focused on leveraging its research on the genetics of epilepsy. Using its insights, the company is currently working on a pipeline of treatments that address the genes that control the imbalance of excitation and inhibition of neuronal circuitry.
